JP2024522167A5 - - Google Patents
Info
- Publication number
- JP2024522167A5 JP2024522167A5 JP2023575549A JP2023575549A JP2024522167A5 JP 2024522167 A5 JP2024522167 A5 JP 2024522167A5 JP 2023575549 A JP2023575549 A JP 2023575549A JP 2023575549 A JP2023575549 A JP 2023575549A JP 2024522167 A5 JP2024522167 A5 JP 2024522167A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- sequence
- antisense oligonucleotide
- pnpla3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163208299P | 2021-06-08 | 2021-06-08 | |
| US63/208,299 | 2021-06-08 | ||
| PCT/IB2022/055292 WO2022259145A1 (en) | 2021-06-08 | 2022-06-07 | Combination therapies for treatment of liver diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024522167A JP2024522167A (ja) | 2024-06-11 |
| JP2024522167A5 true JP2024522167A5 (enExample) | 2025-06-13 |
Family
ID=82214216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023575549A Withdrawn JP2024522167A (ja) | 2021-06-08 | 2022-06-07 | 肝疾患の処置のための併用療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250122504A1 (enExample) |
| EP (1) | EP4352223A1 (enExample) |
| JP (1) | JP2024522167A (enExample) |
| KR (1) | KR20240019796A (enExample) |
| CN (1) | CN117441017A (enExample) |
| AU (1) | AU2022289514A1 (enExample) |
| CA (1) | CA3221482A1 (enExample) |
| IL (1) | IL308974A (enExample) |
| MX (1) | MX2023014723A (enExample) |
| TW (1) | TW202313974A (enExample) |
| WO (1) | WO2022259145A1 (enExample) |
| ZA (1) | ZA202400228B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4724472A2 (en) * | 2023-06-09 | 2026-04-15 | Sun Pharmaceutical Industries Limited | Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists |
| TW202539705A (zh) * | 2024-04-03 | 2025-10-16 | 瑞典商阿斯特捷利康公司 | Ｐｎｐｌａ３表現之抑制劑的劑量依賴性投予 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US8563521B2 (en) | 2007-06-21 | 2013-10-22 | Technische Universitat Munchen | Biological active proteins having increased in vivo and/or in vitro stability |
| TWI617574B (zh) | 2012-12-11 | 2018-03-11 | 梅迪繆思有限公司 | 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑 |
| TWI869213B (zh) * | 2018-09-19 | 2025-01-01 | 美商Ionis製藥公司 | Pnpla3表現之調節劑 |
| CN114728017B (zh) * | 2019-10-14 | 2025-10-28 | 阿斯利康(瑞典)有限公司 | Pnpla3表达的调节剂 |
| CN115176007A (zh) * | 2019-12-16 | 2022-10-11 | 阿尔尼拉姆医药品有限公司 | 含类PATATIN磷脂酶结构域3(PNPLA3)iRNA组合物及其使用方法 |
-
2022
- 2022-05-27 TW TW111119798A patent/TW202313974A/zh unknown
- 2022-06-07 US US18/567,548 patent/US20250122504A1/en active Pending
- 2022-06-07 IL IL308974A patent/IL308974A/en unknown
- 2022-06-07 CA CA3221482A patent/CA3221482A1/en active Pending
- 2022-06-07 JP JP2023575549A patent/JP2024522167A/ja not_active Withdrawn
- 2022-06-07 AU AU2022289514A patent/AU2022289514A1/en not_active Abandoned
- 2022-06-07 KR KR1020247000204A patent/KR20240019796A/ko active Pending
- 2022-06-07 EP EP22733733.4A patent/EP4352223A1/en active Pending
- 2022-06-07 CN CN202280040593.7A patent/CN117441017A/zh active Pending
- 2022-06-07 WO PCT/IB2022/055292 patent/WO2022259145A1/en not_active Ceased
- 2022-06-07 MX MX2023014723A patent/MX2023014723A/es unknown
-
2024
- 2024-01-05 ZA ZA2024/00228A patent/ZA202400228B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3472362B1 (en) | Papd5 and papd7 inhibitors for treating an hepatitis b infection | |
| JP5872162B2 (ja) | アンドロゲン受容体を標的化するｌｎａアンタゴニスト | |
| KR101789603B1 (ko) | Ｔｎｆ 수퍼패밀리 수용체에 대한 스플라이스 스위칭올리고머 및 염증성 질환 치료용 약제학적 조성물 | |
| JP2022048397A (ja) | オリゴマーおよびオリゴマー・コンジュゲート | |
| CN105264091B (zh) | 用于调节tau表达的组合物和方法 | |
| JP2024503609A5 (enExample) | ||
| JP6043347B2 (ja) | 線維芽細胞増殖因子受容体４の発現のアンチセンス調節 | |
| JP2009508527A5 (enExample) | ||
| JP2025512469A (ja) | 筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用 | |
| KR20250004771A (ko) | 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체의 투여 | |
| JP2025512464A (ja) | 筋緊張性ジストロフィーを処置するための筋標的化複合体および製剤 | |
| JP2022552249A5 (enExample) | ||
| TW202113079A (zh) | 經修飾之間隙子寡核苷酸及其使用方法 | |
| EA018986B1 (ru) | Соединения-антагонисты рнк для модуляции активности бета-катенина | |
| JP2014533944A (ja) | Ｓｍｎ２スプライシングの調節のための化合物 | |
| JP2024538859A5 (enExample) | ||
| JP2021502359A5 (enExample) | ||
| US20250122504A1 (en) | Combinations with modulators of pnpla3 expression | |
| US20200318113A1 (en) | Polynucleotide conjugates and uses thereof | |
| TW202543656A (zh) | 靶向ＣＩＤＥＢ之ＲＮＡｉ藥劑及相關方法 | |
| TW202517282A (zh) | 用於抑制抑制素次單元βＥ（ＩＮＨＢＥ）之表現的ＲＮＡｉ劑、其醫藥組合物及使用方法 | |
| TW202345861A (zh) | 經修飾之間隔體寡聚物及其使用方法 | |
| AU2011326034A1 (en) | Compositions and methods for treating androgen receptor dependent disorders including cancers | |
| JP2024525078A5 (enExample) | ||
| US20240150768A1 (en) | Methods for the treatment of nash with advanced fibrosis and/or cirrhosis |